Pesquisar no blog...

Mostrando postagens com marcador corticoide. Mostrar todas as postagens
Mostrando postagens com marcador corticoide. Mostrar todas as postagens

segunda-feira, 3 de julho de 2017

Glicocorticóide intra-articular traz poucos benefícios para dor relacionada à osteoartrose de joelho e uso repetido acelera perda de massa cartilaginosa.


Glicocorticóide intra-articular traz poucos benefícios para dor relacionada à 
osteoartrose de joelho e uso repetido acelera perda de massa cartilaginosa.


Lack of benefit of intraarticular glucocorticoid injections for knee osteoarthritis
Although limited evidence suggests that intraarticular glucocorticoid injections for knee osteoarthritis (OA) may result in short-term pain relief, data for longer-term outcomes are less favorable. A randomized trial including 140 patients with symptomatic knee OA and ultrasound features of synovitis found that pain reduction was no different comparing injections of 40 mg triamcinolone acetonide with placebo every 12 weeks for two years [1]. Furthermore, two years of triamcinolone injections resulted in greater cartilage volume loss. These findings do not support intraarticular glucocorticoid injections in patients with symptomatic knee OA and are consistent with our practice. In addition, we discourage the use of serial injections (eg, every three months) due to progressive cartilage damage in knee OA patients.
1. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA 2017; 317:1967.


quarta-feira, 28 de junho de 2017

Quando e como se deve utilizar corticoide na febre de Chikungunya? Fase subaguda e crônica. Doses variam. Vejam fluxogramas compilados

Afinal, quando e como se deve utilizar corticoide na febre de Chikungunya?

A febre de Chikungunya apresenta três fases:
  • Aguda: do início dos sintomas até 14 dias
  • Subaguda: de 14 dias até 3 meses
  • Crônica: mais de 3 meses
Com relação aos sintomas articulares, cerca de 75% permanecem sintomáticos após um mês e cerca de 50% após 3 meses, ou seja, na fase crônica da doença.

Então quando utilizar corticoide?

  1. Não usar na fase aguda da doença (período febril ou com menos de 14 dias de doença)
  2. Não usar corticoides de depósito (Betatrinta, Diprospan etc)
  3. Utilizar nas fases subaguda e crônica da doença, em geral, após não responder ao tratamento com analgésicos, opióides fracos e antiinflamatórios (vejam os algoritmos abaixo)
  4. Utilizar de preferência a prednisona na dose de 10 a 20 mg/dia (recomendações da sociedade brasileira de reumatologia) ou até 0,5 mg/kg (manual de manejo do ministério da saúde).


Seguem os fluxogramas dos manuais do Ministério da Saúde e da Sociedade Brasileira de Reumatologia

Ministério da Saúde





















Sociedade Brasileira de Reumatologia











segunda-feira, 12 de junho de 2017

Corticoide para faringite aguda: pouco benefício, não prescrever de rotina


De novo sobre corticoides...
Estudo mostra benefícios modestos e lembremos dos efeitos colaterais

Dexamethasone and acute pharyngitis pain in adults
Studies of oral glucocorticoids for acute pharyngitis pain have generally found only modest benefit but have been limited by confounding factors such as concurrent antibiotic use. In an office-based randomized trial that compared a single dose of dexamethasone with placebo for adults who visited a primary care clinician for acute pharyngitis and were not given an immediate prescription for antibiotics, there was no difference in the proportion of patients who achieved full pain relief at 24 hours, and there was only a small difference in symptom relief at 48 hours (35 versus 27 percent with placebo) [2]. These results support our suggestion to not prescribe glucocorticoids routinely for acute pharyngitis and to limit their use to severely symptomatic patients.
2. Hayward GN, Hay AD, Moore MV, et al. Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults: A Randomized Clinical Trial. JAMA 2017; 317:1535.




sexta-feira, 2 de junho de 2017

Mesmo cursos breves de corticoides: 2x mais fraturas, 3x mais TVP e 5x a chance de Sepse em um mês




A prescrição de corticoides (e mesmo corticoides de depósito[!]) não tem sido incomum para alívio sintomático de quadros relativamente banais como infecções de vias aéreas sem maiores complicações e outras afecções como dores articulares leve e quadros inflamatórios diversos.




A despeito da melhora sintomática importante que trazem, critérios judiciosos para a prescrição dessas medicações devem ser tomados, pois não são isentos de riscos! Lembrem-se do Dr. Otho: "O corticoide leva o paciente para a mesa de Laennec sorrindo".

Segundo estudo do BMJ, no primeiro mês após uso de corticoides, há 2 vezes mais chances de fratura, 3 vezes mais chance de trombose venosa profunda e 5 vezes o risco de sepse. Esses eventos se manifestaram mesmo com 5-6 dias de curso e com doses de somente 20 mg equivalente de prednisona. 

Vejam mais informações e link para o artigo abaixo.



Even Short-term Oral Steroids Carry Serious Risk

The millions of Americans prescribed short-term oral corticosteroids are taking a dose of risk along with their medication, according to a cohort study of more than 1.5 million adults.

Within 30 days of initiating these drugs, even at relatively low doses, users had a nearly twofold increased risk for fracture, a threefold increased risk for venous thromboembolism, and a fivefold increased risk for sepsis.

"Greater attention to initiating prescriptions of these drugs and monitoring for adverse events may potentially improve patient safety," write Akbar K. Waljee, MD, an assistant professor of gastroenterology at the University of Michigan in Ann Arbor, and colleagues. They present their findings in an article published April 12 in the BMJ.

They found that more than one in five adults included in the Clinformatics DataMart, a large national database of commercial insurance claims, received prescriptions for short-term oral corticosteroids during the 3-year study, which ran from January 1, 2012, to December 31, 2014.

Although corticosteroids are among the most common cause for hospitalization for drug-related adverse events, and various specialties have long focused on optimizing their long-term use, the short-term risks associated with the drugs have been less carefully studied.

"Although physicians focus on the long-term consequences of steroids, they don't tend to think about potential risks from short-term use," said Dr Waljee in a university news release. "We see a clear signal of higher rates of these three serious events within 30 days of filling a prescription. We need to understand that steroids do have a real risk and that we may use them more than we really need to. This is so important because of how often these drugs are used."

Of 1,548,945 adults aged 18 to 64 years included in the database, 327,452 (21.1%) received at least one outpatient prescription for short-term oral corticosteroids (30 or fewer days). The mean age of users was 45.5 years (standard deviation [SD], 11.6 years) compared with 44.1 years (SD, 12.2 years) for nonusers (P < .001). The median duration of use was 6 days (interquartile range, 6 - 12 days).

The six most common indications for the drugs were upper respiratory tract infections, spinal conditions, intervertebral disc disorders, allergies, bronchitis, and nonbronchitic lower respiratory tract disorders. Together, those indications accounted for about half of all prescriptions. The two most common physician specialties prescribing short-term oral corticosteroids were family medicine and general internal medicine.

Nearly half (46.9%) of recipients were prescribed a 6-day prepackaged methylprednisolone "dosepak," which tapers the dose from highest to lowest. Dr Waljee noted in the news release that although individual oral steroid pills can cost less than a dollar each for a 7-day course, the prepackaged version may cost several times that and often initiates therapy with a higher high dose than may be necessary.

Use was more frequent among older patients, women, and white adults, with significant regional variation (all P < .001).

Within 30 days of drug initiation, there was an increase in incidence rate of the following: sepsis, with a rate ratio of 5.30 (95% CI, 3.80 - 7.41); venous thromboembolism, with a rate ratio of 3.33 (95% CI, 2.78 - 3.99); and fracture, with a rate ratio of 1.87 (95% CI, 1.69 - 2.07).

The increased risk persisted at prednisone equivalent doses of less than 20 mg/day, with an incidence rate ratio of 4.02 for sepsis, 3.61 for venous thromboembolism, and 1.83 for fracture (all P < .001).

Rate ratios decreased during the following subsequent 31 to 90 days, however.

Although rare, hospitalizations were also more frequent in users than nonusers, with 0.05% of users admitted for sepsis compared with 0.02% of nonusers. For blood clots, the admission rate was 0.14% versus 0.09%, and for fractures, it was 0.51% vs 0.39%.

Dr Waljee and associates found it significant that the most frequent corticosteroid prescribers were not rheumatologists or other subspecialists experienced in treating inflammatory conditions long-term. "A substantial challenge to improving use of oral corticosteroids will be the diverse set of conditions and types of providers who administer these drugs in brief courses," they write. "This raises the need for early general medical education of clinicians about the potential risks of oral corticosteroids and the evidence basis for their use, given that use may not be specific to a particular disease or specialty."

On the basis of these findings, Dr Waljee recommended prescribing the smallest possible amount of corticosteroids for treating the condition in question. "If there are alternatives to steroids, we should be use those when possible," he said in the release. "Steroids may work faster, but they aren't as risk-free as you might think."

This study was supported partly supported by the University of Michigan's Institute for Healthcare Policy. The authors have disclosed no relevant financial interests.